JP7543290B2 - 抗trem2抗体及びその使用方法 - Google Patents

抗trem2抗体及びその使用方法 Download PDF

Info

Publication number
JP7543290B2
JP7543290B2 JP2021548668A JP2021548668A JP7543290B2 JP 7543290 B2 JP7543290 B2 JP 7543290B2 JP 2021548668 A JP2021548668 A JP 2021548668A JP 2021548668 A JP2021548668 A JP 2021548668A JP 7543290 B2 JP7543290 B2 JP 7543290B2
Authority
JP
Japan
Prior art keywords
seq
sequence
amino acid
cdr
trem2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021548668A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520868A (ja
JP2022520868A5 (cg-RX-API-DMAC7.html
Inventor
マーク エス. デニス
シェリー ダンカン
キャスリーン リサインゴ
キャサリン エム. モンロー
ジョシュア アイ. パーク
レイチェル プロロク
ジュ シー
アンキタ スリヴァスタヴァ
レンゲリッチ ベティーナ ヴァン
ライリー ウォルシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of JP2022520868A publication Critical patent/JP2022520868A/ja
Publication of JP2022520868A5 publication Critical patent/JP2022520868A5/ja
Priority to JP2024139367A priority Critical patent/JP7842822B2/ja
Application granted granted Critical
Publication of JP7543290B2 publication Critical patent/JP7543290B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021548668A 2019-02-20 2020-02-20 抗trem2抗体及びその使用方法 Active JP7543290B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024139367A JP7842822B2 (ja) 2019-02-20 2024-08-21 抗trem2抗体及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962808141P 2019-02-20 2019-02-20
US62/808,141 2019-02-20
PCT/US2020/019093 WO2020172450A1 (en) 2019-02-20 2020-02-20 Anti-trem2 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024139367A Division JP7842822B2 (ja) 2019-02-20 2024-08-21 抗trem2抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2022520868A JP2022520868A (ja) 2022-04-01
JP2022520868A5 JP2022520868A5 (cg-RX-API-DMAC7.html) 2023-02-27
JP7543290B2 true JP7543290B2 (ja) 2024-09-02

Family

ID=69844940

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021548668A Active JP7543290B2 (ja) 2019-02-20 2020-02-20 抗trem2抗体及びその使用方法
JP2024139367A Active JP7842822B2 (ja) 2019-02-20 2024-08-21 抗trem2抗体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024139367A Active JP7842822B2 (ja) 2019-02-20 2024-08-21 抗trem2抗体及びその使用方法

Country Status (21)

Country Link
US (2) US12240902B2 (cg-RX-API-DMAC7.html)
EP (1) EP3927743A1 (cg-RX-API-DMAC7.html)
JP (2) JP7543290B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210135518A (cg-RX-API-DMAC7.html)
CN (1) CN113614110B (cg-RX-API-DMAC7.html)
AR (1) AR118144A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020226754A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021015656A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130086A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002206A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021012230A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192294A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP21069105A (cg-RX-API-DMAC7.html)
IL (1) IL285651A (cg-RX-API-DMAC7.html)
MA (1) MA55025A (cg-RX-API-DMAC7.html)
MX (1) MX2021009722A (cg-RX-API-DMAC7.html)
PE (1) PE20211979A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552002A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108734VA (cg-RX-API-DMAC7.html)
TW (1) TWI879756B (cg-RX-API-DMAC7.html)
WO (2) WO2020172450A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
EP3902836B1 (en) * 2018-12-18 2026-03-25 Boehringer Ingelheim IO Canada Inc. Flt3 agonist antibodies and uses thereof
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
US11124567B2 (en) 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
WO2021146256A1 (en) * 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
EP4232087A4 (en) * 2020-10-21 2024-10-09 Immune-ONC Therapeutics, Inc. NOVEL ANTI-LILRB2 ANTIBODIES AND DERIVED PRODUCTS
WO2022241082A1 (en) * 2021-05-14 2022-11-17 Genentech, Inc. Agonists of trem2
MX2024010324A (es) 2022-02-23 2024-08-30 Alector Llc Metodos de uso de anticuerpos anti-trem2.
EP4499693A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
EP4499695A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
JP2026505005A (ja) 2023-01-30 2026-02-10 イーエスアーエル バイオサイエンス ゲゼルシャフト ミット ベシュレンクテル ハフツング 神経変性障害を治療するためのヒト抗trem2抗体
AU2024320793A1 (en) 2023-08-09 2026-03-12 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
AU2024323186A1 (en) 2023-08-09 2026-01-15 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
KR20260113065A (ko) * 2023-11-15 2026-07-21 머크 샤프 앤드 돔 엘엘씨 인간 넥틴-4 결합제

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523814A (ja) 2014-08-08 2017-08-24 アレクトル エルエルシー 抗trem2抗体及びその使用方法
WO2018195506A1 (en) 2017-04-21 2018-10-25 Amgen Inc. Trem2 antigen binding proteins and uses thereof
JP2018537956A (ja) 2015-10-06 2018-12-27 アレクトル エルエルシー 抗trem2抗体及びその使用方法
WO2019028292A1 (en) 2017-08-03 2019-02-07 Alector Llc ANTI-TREM2 ANTIBODIES AND METHODS OF USE

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
RU2011133071A (ru) 2009-01-06 2013-02-20 Нестек С.А. Переработка макронутриентов
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
US10087408B2 (en) 2010-07-07 2018-10-02 The University Of British Columbia System and method for microfluidic cell culture
US9188593B2 (en) 2010-07-16 2015-11-17 The University Of British Columbia Methods for assaying cellular binding interactions
WO2012176779A1 (ja) * 2011-06-20 2012-12-27 協和発酵キリン株式会社 抗erbB3抗体
CA2909952C (en) 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
EP3041865A2 (en) 2013-09-03 2016-07-13 NovImmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
CN105218669A (zh) 2014-06-10 2016-01-06 河北翰林生物科技有限公司 制备抗人r47h-trem2突变体的人单克隆抗体的方法
KR20240056629A (ko) 2014-09-28 2024-04-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
JP6996979B2 (ja) * 2015-03-31 2022-02-04 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 三量体tnfファミリーリガンドを含む抗原結合分子
WO2017058866A1 (en) * 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
WO2017147509A1 (en) 2016-02-25 2017-08-31 Marco Colonna Compositions comprising trem2 and methods of use thereof
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
JP2019531332A (ja) 2016-07-22 2019-10-31 ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー.ファウ.(デーツェットエンエー) Trem2切断モジュレーター及びその使用
CN118271442A (zh) 2016-12-23 2024-07-02 蓝鳍生物医药公司 抗sez6l2抗体和抗体药物缀合物
US20190367623A1 (en) 2017-01-17 2019-12-05 Yeda Research And Development Co. Ltd. Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
CA3053379A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
CA3053381A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Engineered polypeptides
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
BR112020001060A2 (pt) 2017-07-27 2020-07-14 Novartis Ag variantes de trem2 resistentes a shedase
WO2019032955A1 (en) 2017-08-10 2019-02-14 Denali Therapeutics Inc. MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
WO2019055841A1 (en) 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
WO2019079529A1 (en) 2017-10-17 2019-04-25 The Translational Genomics Research Institute TREM2 AGONISTS FOR STIMULATING MICROGLIA AND IDENTIFICATION METHODS
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
MX2020006213A (es) 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.
BR112020013921A2 (pt) 2018-01-10 2020-12-01 Denali Therapeutics Inc. polipeptídeos de ligação ao receptor de transferrina e usos destes
WO2019246071A1 (en) 2018-06-18 2019-12-26 Denali Therapeutics Inc. Fusion proteins comprising progranulin
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
CA3109763A1 (en) 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
EP3840781A1 (en) 2018-08-22 2021-06-30 Denali Therapeutics Inc. Anti-her2 polypeptides and methods of use thereof
SG11202102162RA (en) 2018-09-11 2021-04-29 Univ Washington Anti-trem-2 agonist antibodies
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
KR102156165B1 (ko) 2018-10-29 2020-09-15 재단법인대구경북과학기술원 인간 trem2 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
CN113302206A (zh) 2018-11-26 2021-08-24 戴纳立制药公司 治疗脂质代谢失调的方法
EP3894864A2 (en) 2018-12-10 2021-10-20 Denali Therapeutics Inc. Lysosomal storage disorder biomarkers and methods of use thereof
CA3122725A1 (en) 2018-12-10 2020-06-18 Mor Research Applications Trem2 antibodies and uses thereof
CA3120875A1 (en) 2018-12-11 2020-06-18 Pionyr Immunotherapeutics, Inc. Methods of using anti-trem2 antibodies
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
AU2020252554B2 (en) 2019-04-03 2026-05-28 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
WO2021146256A1 (en) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
US11124567B2 (en) 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
WO2021158986A1 (en) 2020-02-07 2021-08-12 Denali Therapeutics Inc. Methods for the treatment of hunter syndrome
CA3170338A1 (en) 2020-02-19 2021-08-26 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523814A (ja) 2014-08-08 2017-08-24 アレクトル エルエルシー 抗trem2抗体及びその使用方法
JP2018537956A (ja) 2015-10-06 2018-12-27 アレクトル エルエルシー 抗trem2抗体及びその使用方法
WO2018195506A1 (en) 2017-04-21 2018-10-25 Amgen Inc. Trem2 antigen binding proteins and uses thereof
WO2019028292A1 (en) 2017-08-03 2019-02-07 Alector Llc ANTI-TREM2 ANTIBODIES AND METHODS OF USE

Also Published As

Publication number Publication date
CN113614110A (zh) 2021-11-05
SG11202108734VA (en) 2021-09-29
EP3927743A1 (en) 2021-12-29
PE20211979A1 (es) 2021-10-05
US20220073609A1 (en) 2022-03-10
JP2024164116A (ja) 2024-11-26
TWI879756B (zh) 2025-04-11
BR112021015656A2 (pt) 2021-10-05
CL2021002206A1 (es) 2022-04-22
CO2021012230A2 (es) 2021-09-30
WO2020172457A1 (en) 2020-08-27
CN113614110B (zh) 2025-03-25
PH12021552002A1 (en) 2022-09-19
WO2020172450A1 (en) 2020-08-27
TW202045543A (zh) 2020-12-16
AU2020226754A1 (en) 2021-09-16
IL285651A (en) 2021-09-30
CA3130086A1 (en) 2020-08-27
JP2022520868A (ja) 2022-04-01
EA202192294A1 (ru) 2021-12-24
US12240902B2 (en) 2025-03-04
ECSP21069105A (es) 2021-11-18
MX2021009722A (es) 2021-09-14
JP7842822B2 (ja) 2026-04-08
KR20210135518A (ko) 2021-11-15
AR118144A1 (es) 2021-09-22
MA55025A (fr) 2021-12-29
US20220119522A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
JP7842822B2 (ja) 抗trem2抗体及びその使用方法
US11124567B2 (en) Anti-TREM2 antibodies and methods of use thereof
TWI890727B (zh) 抗trem2 抗體及其使用方法
JP7403441B2 (ja) 抗trem2抗体及びその使用方法
TW201827466A (zh) 抗-tau抗體及使用方法
CN104736185A (zh) 治疗Tau病变的方法
EA049305B1 (ru) Антитела к trem2 и способы их применения
HK40063035A (en) Anti-trem2 antibodies and methods of use thereof
HK40082564A (en) Anti-trem2 antibodies and methods of use thereof
US20250215077A1 (en) Monovalent anti-trem2 binding molecules and methods of use thereof
TW202515915A (zh) 抗pilra抗體、其用途以及相關方法及試劑

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230216

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240401

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240821

R150 Certificate of patent or registration of utility model

Ref document number: 7543290

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150